1. Cardoso CRL, Leite NC, Salles GF. Importance of the hemoglobin glycation index for risk of cardiovascular and microvascular complications and mortality in individuals with type 2 diabetes. Endocrinol Metab (Seoul). 2024; 39:732–47.
2. Ostergaard HB, Mandrup-Poulsen T, Berkelmans GFN, van der Graaf Y, Visseren FLJ, Westerink J, et al. Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. Diabetes Metab. 2019; 45:254–60.
3. van Steen SC, Schrieks IC, Hoekstra JB, Lincoff AM, Tardif JC, Mellbin LG, et al. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial. Eur J Prev Cardiol. 2017; 24:858–66.
4. van Steen SC, Woodward M, Chalmers J, Li Q, Marre M, Cooper ME, et al. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2018; 61:780–9.
5. Klein KR, Franek E, Marso S, Pieber TR, Pratley RE, Gowda A, et al. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ Open Diabetes Res Care. 2021; 9:e002339.
6. Wu JD, Liang DL, Xie Y, Chen MY, Chen HH, Sun D, et al. Association between hemoglobin glycation index and risk of cardiovascular disease and all cause mortality in type 2 diabetic patients: a meta-analysis. Front Cardiovasc Med. 2021; 8:690689.
7. Cohen RM, Lindsell CJ. When the blood glucose and the HbA(1c) don’t match: turning uncertainty into opportunity. Diabetes Care. 2012; 35:2421–3.
8. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes. 2007; 56:1913–21.